Long-Term Outcomes of Resynchronization–Defibrillation for Heart Failure

To the Editor: In the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) by Sapp et al. (Jan. 18 issue), 1 the authors found that the addition of cardiac-resynchronization therapy (CRT) to an implantable cardioverter–defibrillator (ICD) in patients with heart failure reduced all-cause mortality and that the therapeutic benefit of CRT for survival was sustained over a median follow-up of nearly 14 years. We wish to comment on the relatively low enrollment of women. Studies have indicated that long-term all-cause mortality after CRT is higher among men than among women and that women have greater echocardiographic evidence of reverse cardiac remodeling after . . .